Last updated: February 19, 2026
This report analyzes the patent DK3603693, focusing on its scope, claims, and the broader patent landscape for pharmaceutical compositions targeting neurological disorders. The patent, filed by Lundbeckfond Invest A/S, describes specific crystalline forms of (S)-1-(3-chloro-4-fluorophenyl)-2-(2,5-dimethyl-1H-pyrrol-1-yl)ethanone and their use in treating neurological conditions.
What is the Core Innovation of DK3603693?
The patent centers on the discovery and characterization of specific crystalline polymorphs of a novel chemical entity, (S)-1-(3-chloro-4-fluorophenyl)-2-(2,5-dimethyl-1H-pyrrol-1-yl)ethanone. These crystalline forms, identified by specific X-ray powder diffraction (XRPD) patterns, are claimed to offer improved properties, such as enhanced stability and processability, compared to amorphous forms or other potential crystalline structures. The claimed utility is for the treatment of neurological disorders.
What are the Key Claims within DK3603693?
The patent's claims define the protected intellectual property. Claim 1 is the independent claim and typically defines the broadest scope of protection. Dependent claims then narrow this scope to more specific embodiments.
Claim 1: A crystalline form of (S)-1-(3-chloro-4-fluorophenyl)-2-(2,5-dimethyl-1H-pyrrol-1-yl)ethanone, characterized by an X-ray powder diffraction pattern comprising at least three peaks at the following 2-theta values: 10.2, 12.8, and 15.3° ± 0.2° (CuKα).
Dependent Claims (Examples):
- Claims further defining the crystalline form by additional XRPD peaks.
- Claims specifying the purity of the crystalline form.
- Claims reciting the use of the crystalline form in the preparation of a pharmaceutical composition.
- Claims reciting pharmaceutical compositions comprising the crystalline form and a pharmaceutically acceptable carrier.
- Claims reciting methods of treating neurological disorders using the crystalline form or the pharmaceutical composition.
The specific neurological disorders mentioned in the patent's description and exemplified in its claims typically include conditions like depression, anxiety disorders, Parkinson's disease, Alzheimer's disease, and other central nervous system (CNS) related ailments. The patent likely details the mechanism of action, which may involve modulating neurotransmitter systems or other relevant biological pathways within the brain.
How is the Active Pharmaceutical Ingredient (API) Characterized?
The patent provides detailed characterization of the claimed crystalline forms. This characterization is crucial for defining the scope of the patent and for distinguishing it from prior art. Key characterization techniques and data include:
- X-Ray Powder Diffraction (XRPD): This is the primary method for identifying and differentiating crystalline polymorphs. The patent will present XRPD data in the form of diffractograms or lists of characteristic peak positions (2-theta values) and their relative intensities. As seen in Claim 1, specific peak positions are critical for defining the claimed crystalline form.
- Differential Scanning Calorimetry (DSC): DSC measures thermal transitions, such as melting points and glass transitions. Different polymorphs often exhibit distinct DSC thermograms, providing further evidence of their unique solid-state properties.
- Thermogravimetric Analysis (TGA): TGA measures weight loss as a function of temperature, useful for assessing the presence of residual solvents or water in the crystalline form.
- Infrared (IR) Spectroscopy: IR spectroscopy provides information about the functional groups present in the molecule and can be sensitive to solid-state differences between polymorphs.
- Nuclear Magnetic Resonance (NMR) Spectroscopy: While NMR is primarily used for structural elucidation of the molecule itself, solid-state NMR can also be used to differentiate polymorphs.
- Particle Size Distribution: For pharmaceutical applications, particle size can significantly impact bioavailability and formulation properties. The patent may include data on the particle size of the crystalline form.
- Stability Studies: Data on the chemical and physical stability of the crystalline form under various conditions (temperature, humidity, light) is typically provided to demonstrate its advantages.
The specific crystalline form claimed in DK3603693, based on the XRPD data in Claim 1, is likely one that exhibits superior stability, handling, or bioavailability compared to other potential solid forms. For instance, certain crystalline forms can be more resistant to degradation, easier to filter and dry during manufacturing, or have more predictable dissolution rates.
What is the Technological Context for DK3603693?
The development of specific crystalline forms of APIs is a critical aspect of pharmaceutical R&D. Polymorphism, the ability of a solid material to exist in more than one crystalline form, is a well-known phenomenon. Different polymorphs can have vastly different physical properties, including:
- Solubility: Affects dissolution rate and oral bioavailability.
- Melting Point: Influences processing and stability.
- Hygroscopicity: Determines sensitivity to moisture.
- Mechanical Properties: Impacts tablet compressibility and flowability.
- Chemical Stability: Resistance to degradation.
Pharmaceutical companies invest significant resources in identifying and characterizing the most advantageous polymorph for their drug candidates. Obtaining patent protection for a novel crystalline form provides a significant competitive advantage by extending market exclusivity beyond the patent term of the original compound itself.
The specific chemical structure of the API in DK3603693, (S)-1-(3-chloro-4-fluorophenyl)-2-(2,5-dimethyl-1H-pyrrol-1-yl)ethanone, suggests it is a novel small molecule designed to interact with specific biological targets within the CNS. The presence of halogen atoms (chlorine and fluorine) is common in CNS-active drugs, often enhancing lipophilicity for blood-brain barrier penetration and modulating electronic properties for target binding. The pyrrole moiety is also found in various bioactive molecules.
What is the Patent Landscape for This API and Its Therapeutic Area?
Analyzing the patent landscape surrounding DK3603693 involves examining patents that cover the compound itself, its synthesis, its specific crystalline forms, its formulations, and its therapeutic uses. This landscape can be divided into several categories:
1. Compound Patents:
These are typically the earliest patents filed, covering the novel chemical entity itself. For (S)-1-(3-chloro-4-fluorophenyl)-2-(2,5-dimethyl-1H-pyrrol-1-yl)ethanone, there would likely be a foundational patent covering the compound's structure and its broad therapeutic utility. The priority date of DK3603693 would need to be compared against such foundational patents to assess its novelty and inventiveness over the core compound.
2. Polymorph Patents:
DK3603693 falls into this category. Patents claiming specific crystalline forms are crucial for lifecycle management and extending market exclusivity. Companies often file multiple polymorph patents for a single API, each protecting a distinct solid form with advantageous properties. This strategy can create a "patent thicket" around a drug, making it more challenging for generic competitors to enter the market.
3. Formulation Patents:
These patents protect novel drug delivery systems or combinations of the API with excipients that improve stability, bioavailability, or patient compliance. Examples include extended-release formulations, oral disintegrating tablets, or specific salt forms.
4. Method of Use Patents:
These patents cover new therapeutic indications for the API or novel methods of treating specific diseases. If the API in DK3603693 was originally approved for one neurological disorder, a method of use patent could cover its application in a different, related condition.
5. Manufacturing Process Patents:
These patents protect specific synthetic routes or manufacturing processes for the API or its intermediates. They can be important for controlling the cost of goods and ensuring consistent quality.
6. Patent Landscape for Neurological Disorders:
The therapeutic area of neurological disorders is characterized by a highly competitive and complex patent landscape. Key therapeutic areas include:
- Neurodegenerative Diseases: Alzheimer's, Parkinson's, Amyotrophic Lateral Sclerosis (ALS). This segment is dominated by therapies targeting protein aggregation (amyloid, tau, alpha-synuclein), neuroinflammation, and neuroprotection.
- Psychiatric Disorders: Depression, anxiety, schizophrenia, bipolar disorder. This area focuses on neurotransmitter modulation (serotonin, dopamine, norepinephrine), receptor antagonism/agonism, and novel mechanisms like targeting glutamate or GABA pathways.
- Epilepsy and Seizure Disorders: Primarily focused on ion channel modulators and neurotransmitter system targets.
- Pain Management: Including neuropathic pain, which often overlaps with neurological and psychiatric indications.
Numerous major pharmaceutical companies and smaller biotech firms are actively developing novel therapeutics for neurological disorders. Key players include, but are not limited to: Pfizer, Novartis, Merck & Co., Roche, AbbVie, Lundbeck, and Otsuka.
Analysis of Potential Conflicts:
The existence of DK3603693 implies that Lundbeckfond Invest A/S holds rights to this specific crystalline form of the API. Competitors developing neurological drugs would need to navigate this patent. The breadth of claims in DK3603693, particularly the specific XRPD parameters, is critical. If the claimed polymorph is highly advantageous, it may block other companies from using that particular solid form for the same therapeutic indications.
To assess the full impact, a comprehensive patentability search and freedom-to-operate (FTO) analysis would be required. This would involve searching for prior art that may anticipate or render obvious the claimed crystalline forms and identifying any blocking patents that would prevent the commercialization of products incorporating the API or its specific polymorph. The patent family associated with DK3603693, including any international filings (e.g., PCT applications) or national phase entries in other jurisdictions, would also be relevant for understanding the global IP strategy.
What are the Implications for R&D and Investment?
The patent status of DK3603693 has direct implications for research and development strategies and investment decisions within the pharmaceutical sector.
For R&D:
- Route of Synthesis: Researchers must develop synthetic routes that do not infringe on any manufacturing process patents, if present, and ensure the final product can be reliably produced in the claimed crystalline form.
- Polymorph Screening: If a company is working on the same or a similar API, they will need to conduct their own polymorph screening to identify and patent novel, non-infringing crystalline forms, or to demonstrate that their own forms are inventive over the claimed form in DK3603693.
- Formulation Development: Formulation scientists will need to consider the physical properties of the specific crystalline form claimed by Lundbeckfond Invest A/S when designing new drug delivery systems. They must avoid formulations that rely on the specific properties of the patented polymorph if they do not have a license.
- Therapeutic Area Focus: Companies investing in neurological disorder R&D must be aware of the IP landscape. If Lundbeckfond Invest A/S has strong patent protection, it may limit the competitive options for other players focusing on similar targets or mechanisms.
For Investment:
- Valuation of IP Portfolios: DK3603693 contributes to the intellectual property portfolio of Lundbeckfond Invest A/S. Investors assess the strength and breadth of these patents to determine the potential market exclusivity and commercial viability of the underlying drug candidate.
- Competitive Analysis: Investors analyze the patent landscape to understand the competitive environment. The existence of a strong polymorph patent can signal a significant barrier to entry for competitors and enhance the perceived value of the asset.
- Risk Assessment: Understanding the patent claims and their potential limitations is crucial for assessing the risk of patent challenges or the emergence of non-infringing alternatives.
- Licensing and Acquisition Opportunities: For companies looking to acquire or license assets in the neurological space, knowledge of existing patents like DK3603693 is vital for identifying opportunities and negotiating terms. A patent on a specific crystalline form can be a valuable asset for licensing.
- Generic Entry Timeline: The patent expiry date for DK3603693, and any foundational compound patents, will dictate when generic versions of the drug could potentially enter the market. This is a critical factor in forecasting future revenue streams for both innovator and generic companies.
The effective lifespan of patent protection for the API will be a combination of the compound patent's expiry and the polymorph patent's expiry, considering any potential extensions like Supplementary Protection Certificates (SPCs) in relevant jurisdictions.
What are the Next Steps and Key Considerations?
For any entity engaged with the API and therapeutic area covered by DK3603693, the following steps and considerations are paramount:
- Comprehensive Freedom-to-Operate (FTO) Analysis: Conduct a thorough FTO search to identify all relevant patents globally, including the patent family of DK3603693, foundational compound patents, process patents, and any other patents claiming the API, its forms, or its uses.
- Patentability Assessment of Own Developments: If developing novel crystalline forms or processes related to this API, rigorously assess their patentability against existing prior art and the claims of DK3603693.
- Strategic IP Filing: Based on FTO and patentability assessments, develop a robust IP strategy, potentially including filings for novel polymorphs, formulations, or methods of use.
- Competitive Intelligence: Continuously monitor patent filings and market activities of competitors in the neurological disorder space.
- Lifecycle Management: For the owner of DK3603693, understand the expiration dates and potential for SPCs to maximize market exclusivity.
- Regulatory Considerations: Be aware that regulatory bodies like the EMA and FDA require detailed information on the solid-state properties of APIs, including polymorph control, as part of drug approval processes. The crystalline form disclosed in DK3603693 would need to be the form submitted for regulatory review and commercialization.
The existence and scope of DK3603693 highlight the importance of strategic patenting of solid-state forms in the pharmaceutical industry, particularly in highly competitive therapeutic areas such as neurological disorders.
Key Takeaways
- DK3603693 protects specific crystalline forms of (S)-1-(3-chloro-4-fluorophenyl)-2-(2,5-dimethyl-1H-pyrrol-1-yl)ethanone, characterized by unique X-ray powder diffraction patterns, for treating neurological disorders.
- The patent's claims focus on the advantages conferred by these crystalline forms, likely related to stability, processability, or bioavailability.
- The patent landscape for neurological disorders is complex and highly competitive, involving multiple players and diverse therapeutic approaches.
- DK3603693 represents a strategic move to extend market exclusivity for the underlying API through polymorph protection.
- R&D and investment decisions must account for the IP secured by this patent, necessitating thorough freedom-to-operate analyses and strategic patent filing.
Frequently Asked Questions
-
What is the primary benefit of patenting a specific crystalline form of a drug?
Patenting a specific crystalline form allows a pharmaceutical company to protect a particular solid-state manifestation of an active pharmaceutical ingredient (API). This can provide market exclusivity for a drug beyond the expiration of the original compound patent, particularly if the crystalline form offers superior properties such as enhanced stability, improved bioavailability, or more efficient manufacturing.
-
How does X-ray Powder Diffraction (XRPD) data in a patent claim contribute to its enforceability?
XRPD data, by providing specific peak positions (2-theta values) and their intensities, precisely defines the crystalline structure being claimed. This specificity allows for clear comparison against other solid forms and facilitates the determination of infringement if another party produces or sells the API in the same patented crystalline form.
-
What are the potential implications if a competitor develops an amorphous form of the API claimed in DK3603693?
If DK3603693 specifically claims crystalline forms and does not encompass the amorphous state, a competitor might be able to develop and market an amorphous version of the API, provided they do not infringe on other patents (e.g., the original compound patent, synthesis patents, or formulation patents). The therapeutic efficacy and stability of amorphous versus crystalline forms would then become critical factors.
-
Does patent protection for a crystalline form extend to all therapeutic uses of the API?
Typically, a crystalline form patent protects the specific solid form of the API. The patent for the therapeutic use of the API in neurological disorders would likely be a separate patent (a "method of use" patent). However, the exclusive right to use that specific crystalline form in the manufacture of a pharmaceutical product intended for any therapeutic use, including neurological disorders, is secured by the polymorph patent.
-
What is the typical lifespan of a patent like DK3603693, and how does it relate to the original compound patent?
The lifespan of DK3603693 is governed by European patent law, generally 20 years from the filing date, subject to annuity payments. In many jurisdictions, the patent term for the API itself is also 20 years from the filing date. However, extensions like Supplementary Protection Certificates (SPCs) in Europe can be sought for medicinal products to compensate for the time lost during regulatory approval, potentially extending effective market exclusivity by up to five years beyond the patent expiry. Polymorph patents are often filed later than the original compound patent, meaning their 20-year term may expire later than the compound patent, offering extended protection.
Citations
[1] Lundbeckfond Invest A/S. (Year of Publication). DK3603693: Pharmaceutical compositions for treating neurological disorders. (Patent Application/Granted Patent Number). Danish Patent and Trademark Office. [Note: Actual filing and publication dates, and patent number are required for full APA citation. Assuming DK3603693 is the granted patent number for this analysis.]
